@article{8e84e6f2e44b463ca9cf335b04b2fdc1,
title = "Blood pressure-attained analysis of ATACH 2 trial",
abstract = "Background and Purpose-We compared the rates of death or disability, defined by modified Rankin Scale score of 4 to 6, at 3 months in patients with intracerebral hemorrhage according to post-treatment systolic blood pressure (SBP)-attained status. Methods-We divided 1000 subjects with SBP ≥180 mm Hg who were randomized within 4.5 hours of symptom onset as follows: SBP <140 mm Hg achieved or not achieved within 2 hours; subjects in whom SBP <140 mm Hg was achieved within 2 hours were further divided: SBP <140 mm Hg for 21 to 22 hours (reduced and maintained) or SBP was ≥140 mm Hg for at least 2 hours during the period between 2 and 24 hours (reduced but not maintained). Results-Compared with subjects without reduction of SBP <140 mm Hg within 2 hours, subjects with reduction and maintenance of SBP <140 mm Hg within 2 hours had a similar rate of death or disability (relative risk of 0.98; 95% confidence interval, 0.74-1.29). The rates of neurological deterioration within 24 hours were significantly higher in reduced and maintained group (10.4%; relative risk, 1.98; 95% confidence interval, 1.08-3.62) and in reduced but not maintained group (11.5%; relative risk, 2.08; 95% confidence interval, 1.15-3.75) compared with reference group. The rates of cardiac-related adverse events within 7 days were higher among subjects with reduction and maintenance of SBP <140 mmHg compared to subjects without reduction (11.2% versus 6.4%). Conclusions-No decline in death or disability but higher rates of neurological deterioration and cardiac-related adverse events were observed among intracerebral hemorrhage subjects with reduction with and without maintenance of intensive SBP goals.",
keywords = "acute hypertensive response, blood pressure, cerebral hemorrhage, clinical trial, humans",
author = "Qureshi, {Adnan I.} and Palesch, {Yuko Y.} and Foster, {Lydia D.} and Barsan, {William G.} and Goldstein, {Joshua N.} and Hanley, {Daniel F.} and Hsu, {Chung Y.} and Moy, {Claudia S.} and Qureshi, {Mushtaq H.} and Robert Silbergleit and Suarez, {Jose I.} and Kazunori Toyoda and Haruko Yamamoto",
note = "Funding Information: This study was supported by grants (U01-NS062091, to Dr A.I. Qureshi; U01-NS061861 and U01-NS059041, to Dr Palesch; and U01-NS056975, to Dr Barsan) from the National Institute of Neurological Disorders and Stroke and by a grant (H23-4-3, to Dr Toyoda) from the Intramural Research Fund for Cardiovascular Diseases of the National Cerebral and Cardiovascular Center. Statistical analysis was conducted by the Department of Public Health Sciences, Medical University of South Carolina, Charleston. Funding Information: L.D. Foster received a research grant from the National Institute of Neurological Disorders and Stroke—statistical and data coordinating center for the ATACH 2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage; 5U01NS061861). She also receives compensation as the Significant (>$10k or 5%). Dr Goldstein receives research grant from Pfizer (Significant; >$10k or 5%), Boehringer Ingelheim (Modest; <$10k or 5%), and Portola (Significant; >$10k or 5%); serves as a consultant or advisory board member for CSL Behring; and also receives compensation (Modest; <$10k or <5%). Dr Hsu was supported by the Ministry of Health and Welfare Clinical Trial Center for Stroke (MOHW104-TDU-B-212-113002) and the Ministry of Science and Technology Taiwan Clinical Trial Consortium for Stroke (MOST 105-2325-B-039 -006). Dr Silbertgleit receives research grant support from the National Institutes of Health (NIH; the University of Michigan received grants from the NIH to perform the clinical trial results reported here). Dr Hanley is a principal investigator at MISTIE trial (Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation; Significant; >$10k or 5%), receives research grant support from MISTIE trial (NIH funded; Significant; >$10k or 5%), and is an expert witness/legal consultant (Modest; <$10k or <5%). The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2018 American Heart Association, Inc.",
year = "2018",
doi = "10.1161/STROKEAHA.117.019845",
language = "English (US)",
volume = "49",
pages = "1412--1418",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}